Drug Profile
Plogosertib - Cyclacel Pharmaceutical
Alternative Names: CY-140; CYC-140Latest Information Update: 28 Apr 2023
Price :
$50
*
At a glance
- Originator Cyclacel Pharmaceuticals
- Developer Cyclacel Pharmaceuticals; M. D. Anderson Cancer Center
- Class Antineoplastics; Small molecules
- Mechanism of Action Polo-like kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Solid tumours
- No development reported Leukaemia; Myelodysplastic syndromes
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Leukaemia(Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO)
- 28 Apr 2023 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes(Late-stage disease, Monotherapy, Refractory metastatic disease, Second-line therapy or greater) in USA (PO)
- 09 Nov 2022 Updated efficacy data from a phase-I/II trial in Solid tumours released by Cyclacel Pharmaceuticals